RxDoctor Payments Data

Himanshu Shukla, MD

Clinical Cardiac Electrophysiology · Ocala, FLNPI 1285627703

Payments from drug & device makers

$84,582in general payments, 2019–2025

Across 508 payments — averaging $166.50 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$77K
  • ZOLL Respicardia, Inc.$4K
  • Novartis$810
  • Johnson & Johnson$359
  • Bardy Diagnostics, Inc.$310
  • Impulse Dynamics (USA) Inc.$293
  • plus $2K from 22 others

What the payments were for

  • Consulting fees$60,49772%
  • Travel & lodging$15,95119%
  • Food & beverage$8,12010%
  • Education$140%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$84,582 in reported general payments places this provider in the 70th percentile of 249 clinical cardiac electrophysiology providers in Florida.

See all clinical cardiac electrophysiology providers in Florida

Medicare billing

Part B allowed, 2024
$1,480,982
Medicare patients
1,405
Services billed
22,557

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban254$317,380
XareltoRivaroxaban76$103,302
JardianceEmpagliflozin37$38,503
EntrestoSacubitril/Valsartan24$33,050
Repatha SyringeEvolocumab13$19,275
Repatha SureclickEvolocumab11$13,464
Dabigatran EtexilateDabigatran Etexilate Mesylate19$6,440
Metoprolol Succinate486$6,175
Atorvastatin Calcium374$3,041
ClopidogrelClopidogrel Bisulfate268$2,919
Ranolazine ErRanolazine14$2,337
Losartan Potassium253$2,287
Nifedipine ErNifedipine98$1,799
Bumetanide34$1,739
Flecainide Acetate45$1,356

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$126$317,380254 claims
Johnson & JohnsonXarelto$359$103,30276 claims
Boehringer IngelheimJardiance$71$38,50337 claims
NovartisEntresto$810$33,05024 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 249 clinical cardiac electrophysiology providers in Florida.

Other clinical cardiac electrophysiology in Ocala

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →